微創醫療科學有限公司 (00853) 公佈旗下上海微創心胸血管醫療科技（集團）有限公司（Endovastec）2025 年前三季度未經審計的關鍵財務數據。Endovastec 為該集團持股 40.32% 的子公司，其各項業績亦併入母公司財務報表。
公告顯示，於 2025 年 1-9 月，Endovastec 實現營業收入約人民幣 1,014,780 千元，同比增長 4.66%，實現利潤約人民幣 497,543 千元，同比下降 21.80%。歸屬於 Endovastec 股東的淨利潤約人民幣 429,056 千元，同比下降 22.46%。截至 2025 年 9 月 30 日，Endovastec 的總資產約人民幣 4,732,363 千元，較 2024 年底增長 10.27%，股東權益約人民幣 3,956,811 千元，較 2024 年底增長 4.352%。上述數據均依照中國會計準則編製，並僅反映 Endovastec 的經營情況。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.